These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10462143)

  • 1. Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus.
    Takeda S; Ueshiba H; Hattori Y; Irie M
    Diabetes Res Clin Pract; 1999 Jun; 44(3):197-205. PubMed ID: 10462143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the calcium channel blocker nilvadipine on urinary albumin excretion in hypertensive microalbuminuric patients with non-insulin-dependent diabetes mellitus.
    Sumida Y; Yano Y; Murata K; Goto H; Ura H; Ezaki J; Tsutsumi S; Shirayama K; Misaki M; Shima T
    J Int Med Res; 1997; 25(3):117-26. PubMed ID: 9178143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and aldosterone levels.
    Tanaka M; Sekioka R; Nishimura T; Ichihara A; Itoh H
    Diabetes Res Clin Pract; 2014 Dec; 106(3):504-10. PubMed ID: 25458339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cilnidipine, a novel dihydropyridine Ca2+ channel blocker, on adrenal catecholamine secretion in anesthetized dogs.
    Nagayama T; Yoshida M; Suzuki-Kusaba M; Hisa H; Kimura T; Satoh S
    J Cardiovasc Pharmacol; 1998 Sep; 32(3):479-84. PubMed ID: 9733363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Determination of urinary catecholamines with neuroblastoma in children by HPLC].
    Chang AW; Wu YM; Wu YJ; Xu D
    Wei Sheng Yan Jiu; 2006 Mar; 35(2):159-61. PubMed ID: 16758959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The L/N-type calcium channel blocker, Cilnidipine, reduces heart rate and albuminuria in patients with type 2 diabetes.
    Tanaka M
    J Int Med Res; 2010; 38(2):602-10. PubMed ID: 20515573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.
    Masuda T; Ogura MN; Moriya T; Takahira N; Matsumoto T; Kutsuna T; Hara M; Aiba N; Noda C; Izumi T
    Cardiovasc Ther; 2011 Feb; 29(1):46-53. PubMed ID: 20337636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the anti-hypertensive effects of the L/N-type calcium channel antagonist cilnidipine, and the L-type calcium channel antagonist amlodipine in hypertensive patients with cerebrovascular disease.
    Takei K; Araki N; Ohkubo T; Tamura N; Yamamoto T; Furuya D; Yanagisawa CT; Shimazu K
    Intern Med; 2009; 48(16):1357-61. PubMed ID: 19687579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nifedipine, captopril and prazosin on secretory function of pancreatic beta-cells in hypertensive patients with type-2 (non-insulin-dependent) diabetes and in hypertensive non-diabetics.
    Jasik M; Kasperska-Dworak A; Czyzyk A
    Diabetes Res Clin Pract; 1996 Jun; 33(1):59-66. PubMed ID: 8877277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients.
    Ito T; Fujimoto N; Ishikawa E; Dohi K; Fujimoto M; Murata T; Kiyohara M; Takeuchi H; Koyabu S; Nishimura H; Takeuchi T; Ito M
    Clin Exp Hypertens; 2019; 41(1):92-99. PubMed ID: 29584458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin levels, physical activity, and urinary catecholamine excretion of obese and non-obese rhesus monkeys.
    Wolden-Hanson T; Davis GA; Baum ST; Kemnitz JW
    Obes Res; 1993 Jan; 1(1):5-17. PubMed ID: 16353346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
    Soeki T; Kitani M; Kusunose K; Yagi S; Taketani Y; Koshiba K; Wakatsuki T; Orino S; Kawano K; Sata M
    Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Fukumoto S; Ishimura E; Motoyama K; Morioka T; Kimoto E; Wakikawa K; Shoji S; Koyama H; Shoji T; Emoto M; Nishizawa Y; Inaba M;
    Diabetes Res Clin Pract; 2012 Jul; 97(1):91-8. PubMed ID: 22336632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard.
    Minami J; Ishimitsu T; Kawano Y; Numabe A; Matsuoka H
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):331-6. PubMed ID: 9700998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of catecholamines by flow-injection analysis and high-performance liquid chromatography with chemiluminescence detection.
    Nalewajko E; Wiszowata A; Kojło A
    J Pharm Biomed Anal; 2007 Apr; 43(5):1673-81. PubMed ID: 17289328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types of calcium channel blockers.
    Konoshita T; Makino Y; Kimura T; Fujii M; Morikawa N; Wakahara S; Arakawa K; Inoki I; Nakamura H; Miyamori I;
    Int J Cardiol; 2013 Jun; 166(2):448-52. PubMed ID: 22112682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension.
    Ogura C; Ono K; Miyamoto S; Ikai A; Mitani S; Sugimoto N; Tanaka S; Fujita M
    Blood Press; 2012 Dec; 21(6):367-71. PubMed ID: 22747420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian variations of urinary dopamine, norepinephrine, epinephrine and sodium in normotensive and hypertensive subjects.
    Kawano Y; Kawasaki T; Kawazoe N; Abe I; Uezono K; Ueno M; Fukiyama K; Omae T
    Nephron; 1990; 55(3):277-82. PubMed ID: 2370928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of manidipine and delapril on glucose and lipid metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Atarashi K; Takagi M; Minami M; Kimura Y; Matsuoka H; Sugimoto T
    Blood Press Suppl; 1992; 3():130-4. PubMed ID: 1343282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.